Aravis


Aravis is a Switzerland based venture capital organisation managing two funds focused on life science (Aravis Biotech I & II) and a third fund focused on renewable energy (Aravis Energy I). Since 1995 the Aravis management team have invested over $600 million in more than 80 companies.

As well as providing venture capital backing, Aravis also takes a hands-on approach to highly promising companies offering a unique international network that combines decades of experience in science, operations and financing.

With a disciplined investment process and Aravis' hands on approach in supporting management, the companies that Aravis has invested in have shown a comparatively low failure rate and many have grown to become some of the leading companies in their fields.

News

14.05.12
Omer entering NASDAQ Biotechnology Index  ...
20.04.12
Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis ...
18.04.12
MerLion Announces Initiation of a Phase III Clinical Programme to Evaluate Finafloxacin for the Treatment of Acute Otitis Media ...
22.03.12
Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug
Discovery Platform ...
22.03.12
Evolva reports financial results for 2011
Saffron - new product in Nutrition pipeline
Further shift towards Nutrition and Consumer products ...
© 2008 Aravis SA  |  Merkurstrasse 70  |  CH 8032 Zuerich  |  Tel. +41 43 499 2000 | Fax +41 43 499 2001  |  Disclaimer  |  Developed by Dogbytes Cretive Worx